Member Info for PM2022

True but as always buy low and sell high by doing research unless you can afford big risks. When you buy based on excitement you have every chance of being caught out on a spike. Here not much downside as we know where this is heading one way or another.

Well when Valrix get a deal for Val 201 soon it for sure will be transformational here and more so at Valirx given the market cap of that company. GIven the value of that deal Physiomics will also explode. Invested in both but more heavily involved in Val.

It has no implications and makes no difference to the share price. It was just in the evaluation stage. We will be adding a new drug into the pipeline for evaluation soon.

At the moment it is really just about Val 201, 301 and 401 but mainly 201 and 401 as they are at stage 2 but val 301 is still being evaluated by a big japanese pharmaceutical and we could get a big deal for that.

I suggest you watch the Q and A from last week which is 1 hour long and explains everything. In my opinion it is a safe investment with no placings due and Val 201 is been the subject of numerous commercial deals and one can be signed in the coming weeks which will be completely transformational given our market cap at the moment. It is clear that Suzy and co seem confident about a 201 deal soon but they cannot comment on timelines but numerous meetings have taken place.

Less than 20 p an absolute bargain.

Not much given away regarding timing of any news but remain confident that partnership for 201 or 301 can drop any day in the coming weeks or months.

I think Kevin was trying to say people should be asking how confident he was regarding a deal for 201 but got cut off a bit.

Maybe they are doing phase 1 trials as well. I can't see them coming back with a rejection after so long and is a clear sign they are interested.

Regardless KTH222 makes no difference to the value of Val as it never added value to the share price in the first place.

Ahoy,

Crunch time for VAL. If ever news was expected then the next few could be huge. Now would be the time to be in. Monday morning RNS very possible and I am sure they have working towards this date.

I expect news this week either Weds or Thurs regarding update for KTH222 although it could be at the end of the month.

Hopefully can see nice rice into mid 30s and 201 partnership can drop any week now. That will be the big one. EIther way now is the time to buy given long overdue news, low price and expected news that is likely to come this month.

https://www.youtube.com/watch?v=gouHhJBHHTI

Peer Group review
We have updated our peer group of London-listed drug developers with oncology assets
at a clinical or preclinical stage. ValiRx’s current market capitalisation is nearly fourfold
less than that of the peer-group median (£52.1m). Given that ValiRx has two clinical
stage assets as well as a preclinical programme, we maintain that this price discrepancy
is unjustified.
Peer-group comparison of London-listed drug developers with oncology assets at a clinical or preclinical stage
Name Ticker Mkt Cap
Median - 52.14
Valirx VAL LN 13.34
Hemogenyx Pharmaceuticals HEMO LN 12.85
Sareum Holdings SAR LN 74.87
Okyo Pharma OKYO LN 52.14
Tiziana Life Sciences TILS LN 166.39
Redx Pharma REDX LN 182.13
Scancell Holdings SCLP LN 169.16
Evgen Pharma EVG LN 21.72
Midatech Pharma MTPH LN 17.43

https://www.asktraders.com/analysis/valirx-shares-rally-8-78-on-upbeat-fy-2020-financial-results-and-operations-update/

SELECTING a commercial partner for VAL201 remains a high priority for ValiRx and completion of the clinical trial and study report at the end of 2020 has enabled us to actively engage with a variety of INTERESTED PARTIES parties. Kevin Cox....I'm happy with that. 201 sooner rather than later id say. How about you Georgie boy? do you like that statement?

To be fair this has been the case for a while and I think many will be trying to partner VAL201 . Kevin said the same in December. A deal is highly likely soon and with current market cap I suspect we could be hearing close to the £1 mark soon. As for cash in the bank how about a few million upfront payment to help us along the way with new projects coming in. Maybe the japanese will join the party soon as well with 301.

Looks like I dodged a bullet here. Almost purchased but got large number of shares in VALRIX as has a very low market cap and numerous potential deals in the making over the next few months. Very promising.

Anyway nothing lasts forever and I am sure this will rise one day.

Normally stocks rise fast in anticipation of results like what we saw in September last year.

Does anyone know any companies that have risen significantly after a similar deal on AIM? Just would be interesting to see how this increase in share price will work and what the deal was.

If dropped suddenly and without any form of update from the board then maybe we will see a rise like Synairgen as the re-rate would have to be very significant given our current market cap and everyone will be jumping in after the RNS.

I know a few red brick university professors who informally always make spelling and grammar mistakes but otherwise can write well. It is rather ignorant to think they would all type perfectly in such a situation.

Hopefully we can rise beyond 24p then the next rise will be 30/35p but news can smash that resistance at any time.

News due this week possibly. We all know how fast this can rise with some momentum. Long overdue.

Entertaining daily soap show. Probably the best board on AIM. Great value for money.

Or they may go a step better this time with news due soon. Could hit above 50p at least if news hits. WIn-WIn situation I guess.

Looks like we had a big breakthrough. Could be huge RNS if it is us. Looking forward to tomorrow.

Well it looks like multiple news due over the next 3 months.

1) Update due either this month or next regarding KTH222

2) Val301 update is very likely in the next 3 months as very overdue.

3) Val 201 talks have been going on for many months/years and should now be concluding. Provided we can satisfy any concerns from any partners we should now be able to conclude with the Physiomics work continuing.

4) Possible external partner update regarding Val401 due.

Given our market cap being only 12 million pounds any positive update can rocket this price. Well worth the wait and I can see a positive update in the next 4 weeks for sure. Limited downside and no immediate placing.

What Val needs is more publicity to attract new shareholders. We have been suffering from low volumes for a while now. An interview with Proactive to discuss our portfolio would be welcome and any media publicity would be nice.

Also I hope Suzy does not have to officially wait to give an update regarding any deals for 201. Hopefully an RNS stating we have had multiple offers but are conducting some final work over the next few weeks/months before determining the partner would also be great and would attract new investors and avoid crashing the price with frustrated long term investors selling on RNS day.

London, UK - ValiRx (AIM: VAL) a clinical stage drug development company, announces today that it has entered into an agreement with Kalos Therapeutics (Kalos), a US-based private biotechnology company, to evaluate its peptide KTH222 as a drug candidate for treating patients with ovarian cancer. This project underscores ValiRx's new strategy to grow a pipeline of innovative, early-stage projects in the area of oncology and women's health.


Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel. At the conclusion of the estimated six-month evaluation schedule (May 2021), ValiRx has the option to enter a full licensing agreement, with KTH222 anticipated to be integrated into a jointly owned ValiRx subsidiary for further clinical development.